Profit before tax was at Rs 116.17 crore in Q4 FY23, improved significantly from Rs 28.66 crore in Q4 FY22.

EBITDA jumped 30% to Rs 205 crore in Q4 FY23 as compared with Rs 158 crore in Q4 FY22. EBITDA margin stood at 15% in Q4 FY23 as against 11% in Q4 FY22.

On the segmental front, API revenue was Rs 313 crore (up 41% YoY). In the Formulations business, US revenue was Rs 354 crore (down 36% YoY), India revenue was Rs 490 crore (up 9% YoY) and Ex-US revenue was Rs 249 crore (up 33% YoY).

R&D expenses aggregated to Rs 136 crore during the quarter while Capex spend stood at Rs 67 crore.

On full year basis, the company's consolidated net profit declined 34.4% to Rs 341.98 crore despite of 6.5% rise in revenue from operations to Rs 5,652.62 crore in FY23 over FY22.

Pranav Amin, managing director, Alembic Pharmaceuticals, said, “The USA business continues to remain challenging, however, the Company witnessed topline growth across all other verticals. In particular, the API business outperformed with a 41% growth and Ex-US generics with 33% growth during the quarter. We have started commercialization of products from our injectable and oncology facilities. India Branded Business continues to outperform the market especially on focused products / therapeutic segments.”

The board has recommended a dividend of Rs 8 per equity share, subject to approval of shareholders.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.

The scrip declined 0.98% to settle at Rs 554.40 on Friday, 5 May 2023.